Pyoderma Gangrenosum Successfully Treated with Cyclosporin A

V'lckova-Laskoska, Marija; Laskoski, Dimitri S.; Caca‐Biljanovska, Nina; Darkoska, J. S.

doi:10.1007/978-1-4615-4857-7_81

Cited by 9 publications

(3 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…After 3 months of treatment, PPG had completely resolved and there were no major side effects. 8 Other potential topical therapies that control inflammation and promote wound healing include benzoyl peroxide, chlormethine (topical alkylating agent and nitrogen mustard that has anti-inflammatory properties), nicotine, and 5-aminosalicylic acid. If an ulcer becomes infected, empiric antibiotic therapy should be given immediately and adjusted based on culture and sensitivity results.…”

Section: U T I S D O N O T C O P Ymentioning

confidence: 99%

“…Studies have shown that patients demonstrate clinical improvement within 3 weeks of cyclosporine initiation, and it has been shown further to be more effective than either azathioprine or methotrexate. 4,8 Infliximab, a chimeric antibody that binds both circulating and tissue-bound TNF-α, has been shown to effectively treat PPG. A clinical trial conducted by Brooklyn et al 9 found that 46% of patients (6/13) treated with infliximab responded compared with only 6% in a placebo control group (1/17).…”

Section: U T I S D O N O T C O P Ymentioning

confidence: 99%

See 1 more Smart Citation

Peristomal Pyoderma Gangrenosum at an Ileostomy Site

Guda¹

2022

Cutis

View full text Add to dashboard Cite

Section: U T I S D O N O T C O P Ymentioning

confidence: 99%

Section: U T I S D O N O T C O P Ymentioning

confidence: 99%

Peristomal Pyoderma Gangrenosum at an Ileostomy Site

Guda¹

2022

Cutis

View full text Add to dashboard Cite

“…Ein besonders rascher Erfolg lässt sich mit intravenöser Applikation von Ciclosporin A erzielen [13,23,24,36,47,48,64,94,101,119,140,151,172,182]; allerdings ist diese Therapie nicht risikolos. Nephrotoxizität und infektiöse Folgen der Immunsuppression zählen zu den häufigsten Nebenwirkungen.…”

Section: Häufige Hautmanifestationen Bei Cedunclassified

Extraintestinale Manifestationen bei chronisch-entz�ndlichen Darmerkrankungen*

Rogler

Schölmerich²

2004

Medizinische Klinik

View full text Add to dashboard Cite

Extraintestinal manifestations of Crohn's disease and ulcerative colitis are found in > 50% of all patients. These extraintestinal manifestations sometimes impair the overall life quality much more than the bowel-related symptoms. Extraintestinal manifestations need to be distinguished from secondary diseases or complications of inflammatory bowel diseases, as they require a different and specific therapy. Complications of the intestinal disease, such as vitamin deficiency or osteoporosis, can be treated specifically by substitution of vitamin D, calcium, or other vitamins. However, extraintestinal manifestations of Crohn's disease and ulcerative colitis, such as primary sclerosing cholangitis, arthritis or granulomatous inflammation of the skin, lung, or liver, are much more difficult to treat sufficiently. Almost every organ can be a localization of extraintestinal symptoms of inflammatory bowel diseases. It is important to acquire knowledge on these extraintestinal manifestations of Crohn's disease and ulcerative colitis to start the respective treatment early. Perhaps even more important, these extraintestinal symptoms can be the primary manifestation of Crohn's disease and ulcerative colitis. Therefore, they have to be recognized as extraintestinal manifestations to adequately treat the intestinal disease.

show abstract

Palliative care in inflammatory bowel disease: An evidence-based approach

Gerson¹,

Triadafilopoulos²

2007

Inflamm Bowel Dis

View full text Add to dashboard Cite

The management of the patient with inflammatory bowel disease (IBD) is challenging for both the physician and the patient. IBD imposes both a physical and emotional burden on patients' lives. Palliative care is important for IBD patients because it focuses on improving quality of life. While palliative care does not change the natural history of the disease, it provides relief from pain and other distressing symptoms. This article focuses on various aspects of care for IBD patients including pain control, management of oral and skin ulcerations, stomal problems in IBD patients, control of nausea and vomiting, management of chronic diarrhea and pruritus ani, evaluation of anemia, treatment of steroid‐related bone disease, and treatment of psychological problems associated with IBD. Each of these areas is reviewed using an evidence‐based approach. Evidence in category A refers to evidence from clinical trials that are randomized and well controlled. Category B Evidence refers to evidence from cohort or case‐controlled studies. Category C is evidence from case reports or flawed clinical trials. Evidence from category D is limited to the clinical experience of the authors. Evidence labelled as category E refers to situations where there is insufficient evidence available to form an opinion. Algorithms for management of pain and nausea in IBD patients are presented.

show abstract

Pyoderma Gangrenosum Successfully Treated with Cyclosporin A

Cited by 9 publications

References 6 publications

Peristomal Pyoderma Gangrenosum at an Ileostomy Site

Peristomal Pyoderma Gangrenosum at an Ileostomy Site

Extraintestinale Manifestationen bei chronisch-entz�ndlichen Darmerkrankungen*

Palliative care in inflammatory bowel disease: An evidence-based approach

Contact Info

Product

Resources

About